Medexus Pharmaceuticals Inc. MDP.TO
As ofNov 13, 2026, 4:00 PM EST
- YTD
- +86.60%
- 1 year
- +101.86%
- Market cap
- 170.64M
- Revenue (ttm)
- 104.76M
- Profit margin
- 2.19%
- EPS (ttm)
- -0.10
- Shares out
- 24.65M
- Forward P/E
- -152.50
- YTD return
- +86.60%
- 1-year return
- +101.86%
- Volume
- 59.15K
- Avg volume
- 39.18K
- Open
- 5.69
- Previous close
- 5.69
- Day's range
- 5.37 – 5.69
- 52-week range
- 2.51 – 5.72
- Beta
- 1.95
Key statistics
- Enterprise value
- 105.52M
- PEG ratio
- 0.00
- Price / sales
- 0.72
- Price / book
- 2.30
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- -13.30%
- Free cash flow
- 9.21M
- Total cash
- 6.97M
- Total debt
- 42.97M
- Return on equity
- 8.43%
- Short % of float
- 0.00%
- 50-day average
- 2.53
- 200-day average
- 2.14
About Medexus Pharmaceuticals Inc.
Medexus Pharmaceuticals Inc. operates as a pharmaceutical company in Canada and the United States. The company focuses on the therapeutic areas comprising oncology, hematology, rheumatology, auto-immune diseases, allergy, and dermatology. Its primary products are IXINITY, an intravenous recombinant factor IX therapeutic for use in patients with hemophilia B; Rasuvo and Metoject, a formulation of methotrexate designed to treat rheumatoid arthritis and other auto-immune diseases; Rupall, a prescription allergy medication; and Gleolan, an optical imaging agent indicated in patients with glioma as an adjunct for the visualization of malignant tissue during surgery. The company's products portfolio also includes Cuvposa, a glycopyrrolate oral solution; Naproxen, a Pediapharm naproxen suspension; Otixal, a ciprofloxacin and flucinolone acetonide; Trispan, a triamcinolone hexacetonide injectable suspension; and Trecondyv, a bifunctional alkylating agent for use as part of a conditioning treatment for patients undergoing allogeneic hematopoietic stem cell transplantation. In addition, it offers over the counter products comprising Nyda, a topical revolutionary treatment indicated for the eradication of head lice; Relaxa, an osmotic laxative to treat occasional constipation in adults; Oralvisc to reduce joint pain and enhance joint function in osteoarthritis of the knee; and Calcia Calcium and vitamin D products. The company was formerly known as Pediapharm Inc. and changed its name to Medexus Pharmaceuticals Inc. in December 2018. Medexus Pharmaceuticals Inc. is based in Toronto, Canada.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Country
- Canada
- Website
- medexus.com
News
No recent headlines
Headlines appear here as they are published.
Your note
Sign in to keep a note on MDP.TO — it syncs with the Stock Master app.
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Bard Financial Services, Inc. | 0.04% | 10,000 | 30.50K | Jun 29, 2023 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Perritt Microcap Opportunities Fund | 0.53% | 130,100 | 396.80K | Sep 29, 2024 |
